Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Rapoport, Aaron P  [Clear All Filters]
2023
Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, et al. Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma. Clin Cancer Res. 2023.
2020
Sanchez-Petitto G, Holtzman NG, Bukhari A, Brown M, Morales MK, Koka M, Yared JA, Dahiya S, Rapoport AP, Hardy NM. Toxoplasma-Induced Hemophagocytic Lymphohistiocytosis after Haploidentical Allogeneic Stem Cell Transplantation. Transpl Infect Dis. 2020:e13242.
2019
Godfrey JK, Nabhan C, Karrison T, Kline JP, Cohen KS, Bishop MR, Stadler WM, Karmali R, Venugopal P, Rapoport AP, et al. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019.
2015
Simpson HM, Khan RZ, Song C, Sharma D, Sadashivaiah K, Furusawa A, Liu X, Nagaraj S, Sengamalay N, Sadzewicz L, et al. Concurrent Mutations in ATM and Genes Associated with Common γ Chain Signaling in Peripheral T Cell Lymphoma. PLoS One. 2015;10(11):e0141906.
Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015.
2014
Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Xu YYan, Kalos M, Cai L, Bin Fang H-, Weiss BM, Badros A, et al. Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells. Clin Cancer Res. 2014.
Bin Fang H-, Wu TTong, Rapoport AP, Tan M. Survival analysis with functional covariates for partial follow-up studies. Stat Methods Med Res. 2014.